公开(公告)号：US20240392037A1

公开(公告)日：2024-11-28

申请号：US18694046

申请日：2023-01-10

Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education

Inventor： Dimiter Stanchev Dimitrov ,  Xiaojie Chu ,  Steven David Shapiro ,  John W. Mellors ,  Zehua Sun ,  Dusan Baek

IPC: C07K16/40 ,  A61K39/00 ,  A61P35/00

Abstract: This document provides methods and materials involved in binding a binder (e.g., an antibody, antigen binding fragment, and/or antibody domain) to an NE polypeptide. For example, binders (e.g., antibodies, antigen binding fragments, and/or antibody domains) that bind to an NE polypeptide and methods and materials for using one or more such binding molecules to treat a mammal (e.g., a human) having cancer and/or an inflammatory condition are provided.

公开(公告)号：US12150994B2

公开(公告)日：2024-11-26

申请号：US17834597

申请日：2022-06-07

Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education

Inventor： Steven R. Little ,  Michelle L. Guaragno ,  Andrew J. Glowacki ,  Morgan V. Fedorchak ,  Stephen C. Balmert

IPC: A61K38/18 ,  A61K9/00 ,  A61K9/50 ,  A61K31/436 ,  A61K39/39 ,  A61K45/06 ,  A61P27/02 ,  A61P27/04 ,  A61K38/20 ,  A61K39/00

Abstract: A method for treating an ocular disorder in a subject comprising administering a therapeutic agent-loaded carrier to an ocular site of the subject in need thereof, wherein the therapeutic agent loaded-carrier provides controlled delivery of the therapeutic agent under conditions suitable for recruiting regulatory T cells to an ocular region of interest or inducing regulatory T cells in an ocular region of interest.

公开(公告)号：US20240374681A1

公开(公告)日：2024-11-14

申请号：US18688651

申请日：2022-09-02

Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education

Inventor： Lisa Cencia Rohan ,  Xin Tong ,  Lin Wang

IPC: A61K38/16 ,  A61K9/00 ,  A61K9/19 ,  A61K31/675 ,  A61K47/26

Abstract: Provided herein are stable hypotonic or isotonic formulations containing active ingredients, such as antiviral compositions, or anti-retroviral compositions for intrarectal delivery to provide prophylaxis against viral infections.

公开(公告)号：US20240374240A1

公开(公告)日：2024-11-14

申请号：US18690699

申请日：2022-09-09

Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education ,  North Carolina State University ,  Blatek Industries, Inc.

Inventor： Kim Kang ,  Qiyang Chen ,  Zhiyu Sheng ,  Bohua Zhang ,  Howuk Kim ,  Huaiyu Wu ,  Xiaoning Jiang ,  Mengyue Chen ,  Xuecang Geng

IPC: A61B8/08 ,  A61B8/00

Abstract: Ultrasound systems and methods of use are provided for rapidly heating a target area of a subject. The ultrasound system can include at least one imaging transducer array for imaging the target area, and at least two spaced-apart heating transducer arrays for heating the target area. The heating transducer arrays can be separated by the imaging transducer array on an ultrasound probe.

公开(公告)号：US12115079B2

公开(公告)日：2024-10-15

申请号：US17600259

申请日：2020-04-15

Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education

Inventor： Patrick Peter Bosch

IPC: A61F2/36 ,  A61F2/32 ,  A61F2/30

CPC classification number: A61F2/3609 ,  A61F2/32 ,  A61F2002/30062 ,  A61F2002/30462 ,  A61F2002/30566 ,  A61F2002/3233

Abstract: Hip tethering devices comprise a femoral implant including a housing that anchors the femoral implant to the femur, at least one spring, and a slider, such that the slider can move relative to the housing via compression and expansion of the at least one spring. A tether has a first end that anchors to the acetabulum, the tether passes through the femoral head, and a second end couples to the slider of the femoral implant, such that the tether spans across the patient's hip joint and relative motion between the slider and the housing allows a limited degree of separation of the femoral head from the acetabulum, while the at least one spring applies a variable tension load to the tether that resists separation of the femoral head from the acetabulum.

公开(公告)号：US20240336663A1

公开(公告)日：2024-10-10

申请号：US18579170

申请日：2022-07-15

Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education

Inventor： Samira KIANI ,  Tahere MOKHTARI

IPC: C07K14/435 ,  A61K38/00 ,  A61K48/00 ,  A61P29/00 ,  C12N15/86

CPC classification number: C07K14/435 ,  A61K48/005 ,  A61P29/00 ,  C12N15/86 ,  A61K38/00 ,  C07K2319/81 ,  C12N2750/14143

Abstract: A non-naturally occurring zinc finger protein, wherein the zinc finger protein specifically binds to the promoter region of the Myd88 gene, is provided, as well as related polynucleotides, vectors, cells, and pharmaceutical compositions. In some aspects, the zinc finger protein comprises one or more repressors. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier and: (A) one or more RNA interference (RNAi) agents targeting the Myd88 gene, or related polynucleotides, vectors, or cells: (B) a target antigen or a polynucleotide encoding the target antigen; and (C) a gene therapy are also provided. Methods for ameliorating inflammation and/or immune response in a subject using the RNAi agents, zinc finger protein, polynucleotides, vectors, cells, and pharmaceutical compositions also are provided.

公开(公告)号：US20240335408A1

公开(公告)日：2024-10-10

申请号：US18619902

申请日：2024-03-28

Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education

Inventor： Anthony J. Kanai ,  Irina Zabbarova ,  Youko Ikeda

IPC: A61K31/197 ,  A61K31/192 ,  A61K31/47 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06

CPC classification number: A61K31/197 ,  A61K31/192 ,  A61K31/47 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06

Abstract: Provided herein are methods of treating cancer and fibrosis in a patient. The cancer may be prostate cancer. The fibrosis may be cystitis arising from a cancer therapy, such as from treatment of prostate cancer. The methods involve activation of senescent cells, such as senescent cancer cells with a soluble guanylate cyclase activator. The treatment with the soluble guanylate cyclase activator may be a primary therapy or an adjuvant therapy to a primary cancer therapy such as a chemotherapy or radiation therapy. The treatment may be administered after completion of a primary cancer therapy.

公开(公告)号：US20240335372A1

公开(公告)日：2024-10-10

申请号：US18294226

申请日：2022-08-02

Applicant: University of Pittsburgh-Of the Commonwealth System of Higher Education

Inventor： Lisa Cencia Rohan ,  Prithivirajan Durairajan ,  Sravan Kumar Patel

IPC: A61K9/00 ,  A61K9/70 ,  A61P31/12

CPC classification number: A61K9/0036 ,  A61K9/7007 ,  A61P31/12

Abstract: Provided herein are stable, bioerodible films containing active ingredients, such as antimicrobial composition, antiviral compositions, antiretroviral compositions, and/or contraceptive compositions for intravaginal placement to provide prophylaxis against viral infections and contraception.

公开(公告)号：US12110316B2

公开(公告)日：2024-10-08

申请号：US17287480

申请日：2019-10-18

Applicant: University of Pittsburgh—Of the Commonwealth System of Higher Education

Inventor： Alan H. Wells

IPC: C07K14/52 ,  C12N9/64 ,  A61K38/00

CPC classification number: C07K14/522 ,  C12N9/6491 ,  A61K38/00

Abstract: Recombinant C-X-C motif chemokine ligand (CXCL) peptides modified to introduce a cleavage site for a protease, such as a protease activated during an inflammatory response, are described. The CXCL peptides have the capacity to activate CXCR3 until being cleaved by the protease. Proteolytic cleavage of the CXCL peptide minimizes the pro-inflammatory response and inhibits the development of fibrosis.

公开(公告)号：US20240325537A1

公开(公告)日：2024-10-03

申请号：US18580954

申请日：2022-07-19

Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education

Inventor： Greg M. Delgoffe ,  Ronal Peralta

IPC: A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/113

CPC classification number: A61K39/464412 ,  A61K39/4611 ,  A61K39/4644 ,  A61K39/464404 ,  A61K39/464406 ,  A61K39/464417 ,  A61K39/464424 ,  A61K39/464466 ,  A61K39/464468 ,  A61K39/46447 ,  A61K39/464474 ,  A61K39/464482 ,  A61K39/464494 ,  A61K45/06 ,  A61P35/00 ,  C07K14/7051 ,  C12N5/0636 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/20 ,  C12N2310/531 ,  C12N2501/2302 ,  C12N2510/00

Abstract: The present disclosure provides compositions, including modified peripheral blood mononuclear cells (PBMCs) with reduced expression of Slc16a11 and/or reduced activity of MCT11. Also provided are siRNAs and gRNAs targeting Slc16a11. Methods of using the disclosed compositions in the treatment of cancer are also provided.